Evaluation of arsenic trioxide by the pediatric preclinical testing program with a focus on Ewing sarcoma

From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia

(2011) S.-J. Chen et al.   BLOOD

Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway

(2010) Elspeth M. Beauchamp et al.   JOURNAL OF CLINICAL INVESTIGATION

National Cancer Institute pediatric preclinical testing program: Model description for in vitro cytotoxicity testing

(2010) Min H. Kang et al.   PEDIATRIC BLOOD & CANCER

Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector

(2010) J. Kim et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Arsenic Trioxide Controls the Fate of the PML-RAR  Oncoprotein by Directly Binding PML

(2010) X. W. Zhang et al.   SCIENCE

A pharmacokinetic and safety study of intravenous arsenic trioxide in adult cancer patients with renal impairment

(2009) Christopher J. Sweeney et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

GLI1 Is a Direct Transcriptional Target of EWS-FLI1 Oncoprotein

(2009) Elspeth Beauchamp et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Arsenic trioxide is highly cytotoxic to small cell lung carcinoma cells

(2009) H. M. Pettersson et al.   MOLECULAR CANCER THERAPEUTICS

Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia

(2009) J. Hu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma

(2007) E. Fox et al.   BLOOD